Clinical Trials Logo

Filter by:
NCT ID: NCT03856047 Completed - Obesity Clinical Trials

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take one injection once a week or once a day, depending on the treatment. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 8 months. Participants will have 12 clinic visits with the study doctor.

NCT ID: NCT03855332 Completed - Clinical trials for Small Vessel Cerebrovascular Disease

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

OxHARP
Start date: July 11, 2019
Phase: Phase 2
Study type: Interventional

Chronic damage to small blood vessels deep in the brain is seen in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and almost half of patients with dementia. However, there is limited evidence for how small vessel disease develops and no specific treatment. One potential explanation is that greater pulsations in blood pressure are transmitted to the brain through stiff blood vessels, resulting in increased pressure hitting the brain each time the heart beats and reduced blood flow between heart beats. Sildenafil is used to open up blood vessels (a vasodilator) in patients with erectile difficulties or poor blood supply to the lungs. This trial will test sildenafil (50mg, thrice daily) against placebo and a similar drug (cilostazol 100mg, twice daily) in 75 patients with previous stroke or mini-stroke and small vessel disease, given in random order to every participant for 3 weeks each. It will primarily assess changes in pulsations of blood flow to the brain on each tablet, measured with an ultrasound scanner (transcranial ultrasound). To understand why any changes occur, we will also measure the stiffness of arteries, the blood pressure at the heart and how much blood vessels in the brain open up when participants breathe air with added carbon dioxide (6%), using ultrasound in all participants and on MRI brain scans in 30 patients. This study will test whether a vasodilator used in other conditions with a good safety profile can reduce pulsations in blood flow to the brain, to assess whether it is a good candidate drug to reduce the progression of small vessel disease in future clinical trials. This would be the first effective treatment for a condition associated with a very high burden of disability.

NCT ID: NCT03855254 Completed - Control Condition Clinical Trials

Psychological Context Effects

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This study explores how contextual effects in the fore of positive and negative communication can affect the effect of an osteopathic technique on pain pressure thresholds.

NCT ID: NCT03855137 Completed - Chronic Migraine Clinical Trials

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Start date: March 11, 2019
Phase: Phase 3
Study type: Interventional

This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.

NCT ID: NCT03854097 Completed - Clinical trials for Peripheral Arterial Disease

Effect of Intermittent Pressure in Patients With PAD

Start date: February 16, 2019
Phase: N/A
Study type: Interventional

The study will evaluate the effect of intermittent negative pressure (INP) on peripheral arterial disease (PAD) patient vascular function and blood flow. Patients will be given either -40mmHg INP or -10mmHg INP which will act as a placebo. Healthy volunteers will be given -40mmHg INP to evaluate changes in vascular function and blood flow with INP in healthy physiology.

NCT ID: NCT03853941 Completed - Diabetes Clinical Trials

Adherence to Activity Limitations in Diabetes

Start date: March 21, 2019
Phase: N/A
Study type: Interventional

This study aims to develop and test a theory-based motivation communication training programme for healthcare professionals working with diabetic foot ulcer patients. The investigators will explore the acceptability of the training programme and examine whether the training leads to changes in healthcare professionals' communication style, and results in greater adherence to treatment recommendations (i.e., reduced weight-bearing) in patients.

NCT ID: NCT03853629 Completed - Cystic Fibrosis Clinical Trials

Air Pollution and Children With Cystic Fibrosis

Start date: February 15, 2017
Phase:
Study type: Observational

1. To determine personal exposure to air pollution in children with cystic fibrosis; 2. To determine airway macrophage uptake of inhaled particulate matter in cystic fibrosis children; 3. To establish whether prostaglandin E2 affects particulate matter removal in airway.

NCT ID: NCT03853382 Completed - Self Harm Clinical Trials

Cognitive Analytic Therapy-informed Containment for Self-Harm (CATCH)

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Non-suicidal self-injury (NSSI) is when somebody engages in self-harm, such as cutting, without meaning to end his or her life. A large number of people engage in NSSI for lots of reasons, for example to cope with emotions. However, currently there are large waiting lists to access psychological therapy through the NHS. Therefore, it is important to research brief therapies so that individuals who engage in NSSI can receive treatment quicker. One potentially helpful therapy suggested is Cognitive Analytic Therapy (CAT), which focuses on patterns in relationships. NSSI can be understood as a way in which people relate to themselves, which suggests that CAT would fit well in terms of understanding and working with these difficulties. This study aims to evaluate a brief two-session CAT therapy for people who engage in NSSI. The project aims to evaluate the feasibility and acceptability of the therapy, using interviews and questionnaires. This means looking at whether participants stick with the therapy, and how they find taking part in the therapy. All participants will meet with a researcher for an initial session to complete baseline questionnaires about their current difficulties, thoughts and feelings. Participants will then be randomly allocated to a condition: either the therapy condition or the treatment-as-usual (TAU) condition. Participants in the therapy condition will receive two therapy sessions, whilst participants in the TAU condition will not receive any therapy sessions. All participants will attend a final session to complete more questionnaires. Participants will be asked to complete online surveys weekly. Some participants will be invited to take part in interviews about their experience of the therapy. All participants will receive a shopping voucher as compensation for their time. Using the data collected from this study, future work can be done to provide better treatment for people who engage in NSSI.

NCT ID: NCT03853343 Completed - Metabolic Syndrome Clinical Trials

Seaweed Extract Supplementation and Metabolic Biomarkers

Start date: June 28, 2018
Phase: N/A
Study type: Interventional

Double blinded, randomized, placebo controlled preliminary pilot exploratory investigation into the effects of brown seaweed extract supplementation, on fasting blood Insulin, fasting blood glucose, insulin sensitivity, blood inflammatory markers and tolerance in healthy overweight adults.

NCT ID: NCT03853109 Completed - Clinical trials for Advanced Solid Tumors

AMG 404 in Patients With Advanced Solid Tumors

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.